# Doug Roeder

> Doug Roeder is a Series D investor at Delphi Ventures backing Health Care and Medical Device. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures)
- Location: San Mateo, United States
- Total investments: 14
- Last investment: Apr 2015
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/doug-roeder-01050374

Doug Roeder is a General Partner at Delphi Ventures. Doug holds an AB from Dartmouth College.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 64% |
| Medical Device | 9 | 64% |
| Biotechnology | 4 | 29% |
| Medical | 3 | 21% |
| Health Diagnostics | 2 | 14% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 4 | 29% |
| Series E | 2 | 14% |
| Funding Round | 2 | 14% |
| Series A | 1 | 7% |
| Series B | 1 | 7% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EBR Systems | EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $20M |  | Apr 08, 2015 |  |
| Ivantis | Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $25M | Series B | Sep 23, 2014 |  |
| EBR Systems | EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $18.7M |  | Jul 01, 2014 |  |
| Senseonics | Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. | $20M |  | Jun 05, 2014 |  |
| Ivantis | Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $14M | Series B | Jan 13, 2014 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $40M | Series E | Nov 18, 2013 |  |
| Ivantis | Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $27M | Series B | Jan 31, 2013 |  |
| Labcyte | Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy atlow vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners.Labcyte was founded in 2000 and is based in San Jose, California, United States. | $5.3M | Series D | Jan 08, 2013 |  |
| Tandem Diabetes Care | Tandem diabetes care provides products that empower both people with diabetes and those who care for them. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. | $36.4M | Series D | Sep 11, 2012 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M | Series D | Jun 04, 2012 |  |

10 of 14 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 8 deals together
- [Split Rock Partners](https://shizune.co/investors/profile/split-rock-partners) — VC Fund, 4 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 3 deals together
- [MemorialCare Innovation Fund](https://shizune.co/investors/profile/memorialcare-innovation-fund) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 2 deals together

## About Delphi Ventures

VC Fund · San Mateo, United States

Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by aleading healthcare corporation.

5 contacts available at Delphi Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Deepika R Pakianathan | General Partner | https://shizune.co/investors/profile/deepa-r-pakianathan |
| Doug Roeder | General Partner | https://shizune.co/investors/profile/doug-roeder |
| James Bochnowski | Founder & Managing Member | https://shizune.co/investors/profile/james-j-bochnowski |
| Matthew T. Potter | CFO\| Partner | https://shizune.co/investors/profile/matthew-t-potter |
| David L. Douglass | General Partner | https://shizune.co/investors/profile/david-l-douglass |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Doug Roeder invest in?

Doug Roeder invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series D and Series E stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Doug Roeder last invest?

The most recent investment recorded for Doug Roeder closed in Apr 2015. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co